share_log

WORK Medical Technology Group Announces The Underwriter Of Its IPO Partially Exercised Its Over-Allotment Option, Bringing The Total Ordinary Shares Sold To 2,091,942 And Gross Proceeds To ~$8.37M

WORK Medical Technology Group Announces The Underwriter Of Its IPO Partially Exercised Its Over-Allotment Option, Bringing The Total Ordinary Shares Sold To 2,091,942 And Gross Proceeds To ~$8.37M

WORk醫療科技集團宣佈其IPO的包銷商部分行使了超額配售選擇權,使得總普通股銷售量達到2,091,942股,總收益約爲8.37百萬美元
Benzinga ·  08/30 04:41

WORK Medical Technology Group LTD (NASDAQ:WOK) (the "Company"), a supplier of medical devices in China, today announced the underwriter of its initial public offering (the "Offering") has partially exercised its over-allotment option to purchase an additional 91,942 ordinary shares at the public offering price of US$4.00 per share. After giving effect to the partial exercise of the over-allotment option, the total number of ordinary shares sold by the Company in the public offering increased to 2,091,942 ordinary shares and the gross proceeds increased to approximately $8.37 million, before deducting underwriting discounts and offering expenses payable by the Company. The option closing date was August 29, 2024. The ordinary shares began trading on the Nasdaq Capital Market on August 23, 2024, under the ticker symbol "WOK."

WORk醫療科技集團有限公司(納斯達克:WOK)(以下簡稱「公司」)是中國的醫療設備供應商,今天宣佈首次公開發行(以下簡稱「發行」)的承銷商已部分行使超額配售權,以以每股4.00美元的發行價購買額外的91,942股普通股。在行使超額配售權的部分後,公司在公開發行中的普通股總數增至2,091,942股,總募集資金增至大約83.7萬美元,扣除公司支付的承銷折扣和發行費用。選項截止日期爲2024年8月29日。普通股於2024年8月23日在納斯達克資本市場上市,股票代碼爲「WOk」。

Proceeds from the Offering will be used for (i) upgrading production equipment and increasing production capacity, (ii) developing masks, other medical consumables and medical devices, (iii) product marketing, (iv) patent purchases, and (v) working capital and other general corporate purposes.

發行所得將用於(i)升級生產設備和擴增生產能力,(ii)開發口罩、其他醫療耗材和醫療設備,(iii)產品營銷,(iv)購買專利,(v)營運資金和其他一般企業用途。

The Offering was conducted on a "firm commitment" basis. Kingswood Capital Partners, LLC ("Kingswood") acted as the sole book running manager for the Offering. Hunter Taubman Fischer & Li LLC acted as U.S. counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. counsel to Kingswood in connection with the Offering.

發行是以「堅定承諾」方式進行的。Kingswood Capital Partners, LLC(簡稱「Kingswood」)擔任發行的唯一主承銷商。Hunter Taubman Fischer & Li LLC擔任公司的美國法律顧問,Ortoli Rosenstadt LLP擔任Kingswood的美國法律顧問。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論